Intellia Therapeutics Announces New Positive Clinical Data :

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Hamburg , Germany , Ian Karp , John Leonard , Alina Li , Timothyj Craig , Matt Crenson , Exchange Commission , Twitter , Corporate Communications , Intellia Therapeutics Inc , Biomedical Sciences At Penn State University , Nasdaq , European Academy Of Allergy , Clinical Program , Extended Phase , European Academy , Clinical Immunology , Hybrid Congress , Intellia President , Chief Executive Officer , Rate Reduction , Biomedical Sciences , Penn State University , Intellia Therapeutics , Private Securities Litigation Reform Act , Vice President , Investor Relations ,